Array of cutaneous adverse effects associated with sorafenib.
作者信息
Kong Heidi H, Turner Maria L
出版信息
J Am Acad Dermatol. 2009 Aug;61(2):360-1. doi: 10.1016/j.jaad.2009.02.004.
Abstract
摘要
相似文献
1
Array of cutaneous adverse effects associated with sorafenib.与索拉非尼相关的一系列皮肤不良反应。
J Am Acad Dermatol. 2009 Aug;61(2):360-1. doi: 10.1016/j.jaad.2009.02.004.
2
Sorafenib-induced eruption resembling pityriasis rubra pilaris.
J Am Acad Dermatol. 2011 Aug;65(2):452-453. doi: 10.1016/j.jaad.2010.03.015.
3
Invasive squamous cell carcinoma and sorafenib in a black patient.一名黑人患者的侵袭性鳞状细胞癌与索拉非尼
Arch Dermatol. 2011 Jan;147(1):133-4. doi: 10.1001/archdermatol.2010.395.
4
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.接受多靶点激酶抑制剂索拉非尼和舒尼替尼治疗的患者的皮肤不良反应。
Br J Dermatol. 2009 Nov;161(5):1045-51. doi: 10.1111/j.1365-2133.2009.09290.x. Epub 2009 May 5.
5
Sorafenib-induced eruptive melanocytic lesions.索拉非尼诱发的暴发性黑素细胞性损害。
Arch Dermatol. 2008 Jun;144(6):820-2. doi: 10.1001/archderm.144.6.820.
6
Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.多激酶抑制剂索拉非尼和舒尼替尼的皮肤毒性。
Dermatol Ther. 2011 Jul-Aug;24(4):396-400. doi: 10.1111/j.1529-8019.2011.01435.x.
7
Keratoacanthomas associated with sorafenib therapy.与索拉非尼治疗相关的角化棘皮瘤
J Am Acad Dermatol. 2007 Jan;56(1):171-2. doi: 10.1016/j.jaad.2006.10.032.
8
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.索拉非尼引起手足皮肤反应的风险：一项系统评价和荟萃分析。
Acta Oncol. 2008;47(2):176-86. doi: 10.1080/02841860701765675.
9
[Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].多激酶抑制剂索拉非尼和舒尼替尼的皮肤副作用
Hautarzt. 2010 Aug;61(8):662-7. doi: 10.1007/s00105-010-1942-7.
10
Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome.索拉非尼诱发的全身性红斑性皮肤疹：皮肤毒性和治疗结果
Clin Transl Oncol. 2008 Dec;10(12):844-6. doi: 10.1007/s12094-008-0299-1.
引用本文的文献
1
Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib.酪氨酸激酶抑制剂治疗慢性髓性白血病期间出现的毛发角化病样皮疹：文献综述及1例与伊马替尼相关病例报告
J Clin Med. 2023 Dec 20;13(1):32. doi: 10.3390/jcm13010032.
2
Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).与酪氨酸激酶抑制剂相关的潜在危及生命的严重皮肤不良反应（综述）。
Oncol Rep. 2021 Mar;45(3):891-898. doi: 10.3892/or.2020.7911. Epub 2020 Dec 24.
3
Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.抗肿瘤治疗引起的角化过度性皮肤不良反应：全面综述。
Drug Saf. 2020 May;43(5):395-408. doi: 10.1007/s40264-020-00907-6.
4
Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment.索拉非尼治疗肝癌过程中的结节性囊性皮疹：一种需要非常规治疗的非传统皮肤反应。
Int J Immunopathol Pharmacol. 2017 Sep;30(3):327-331. doi: 10.1177/0394632017727618. Epub 2017 Aug 21.
5
Vandetanib-eluting Radiopaque Beads: Pharmacokinetics, Safety and Toxicity Evaluation following Swine Liver Embolization.凡德他尼洗脱不透射线微球：猪肝栓塞术后的药代动力学、安全性及毒性评估
Theranostics. 2017 Jun 1;7(8):2164-2176. doi: 10.7150/thno.19652. eCollection 2017.
6
Sorafenib-associated facial acneiform eruption.索拉非尼相关的痤疮样皮疹。
Dermatol Ther (Heidelb). 2015 Mar;5(1):77-86. doi: 10.1007/s13555-014-0067-9. Epub 2014 Dec 25.
7
Pharmacological control of receptor of advanced glycation end-products and its biological effects in psoriasis.晚期糖基化终产物受体的药理学调控及其在银屑病中的生物学效应
Int J Biomed Sci. 2013 Sep;9(3):112-22.
8
Dermatological adverse events from BRAF inhibitors: a growing problem.BRAF 抑制剂相关的皮肤不良反应：一个日益严重的问题。
Curr Oncol Rep. 2013 Jun;15(3):249-59. doi: 10.1007/s11912-013-0308-6.
9
Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.摘取低垂的果实：用于治疗晚期髓样甲状腺癌和非髓样甲状腺癌的激酶抑制剂
J Clin Endocrinol Metab. 2010 Jun;95(6):2621-4. doi: 10.1210/jc.2010-0800.
本文引用的文献
1
Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.手足皮肤反应随索拉非尼累积剂量以及联合抗血管内皮生长因子治疗而增加。
Clin Cancer Res. 2009 Feb 15;15(4):1411-6. doi: 10.1158/1078-0432.CCR-08-1141.
2
Dermatologic symptoms associated with the multikinase inhibitor sorafenib.与多激酶抑制剂索拉非尼相关的皮肤症状。
J Am Acad Dermatol. 2009 Feb;60(2):299-305. doi: 10.1016/j.jaad.2008.06.034. Epub 2008 Nov 25.
3
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.新型多激酶抑制剂索拉非尼皮肤不良反应的前瞻性研究。
Arch Dermatol. 2008 Jul;144(7):886-92. doi: 10.1001/archderm.144.7.886.
4
Sorafenib-induced eruptive melanocytic lesions.索拉非尼诱发的暴发性黑素细胞性损害。
Arch Dermatol. 2008 Jun;144(6):820-2. doi: 10.1001/archderm.144.6.820.
5
Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib.在一名接受索拉非尼治疗的患者中，白细胞破碎性血管炎伪装成手足综合征。
Arch Dermatol. 2006 Nov;142(11):1510-1. doi: 10.1001/archderm.142.11.1510.
Zotero 插件